<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856817</url>
  </required_header>
  <id_info>
    <org_study_id>HOADO</org_study_id>
    <nct_id>NCT00856817</nct_id>
  </id_info>
  <brief_title>Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether heme oxygenase 1 induction by heme arginate
      treatment is of influence on adenosine induced vasodilation in healthy individuals.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment faillure. Similar study published by others. Not yet entered treatment phase.
  </why_stopped>
  <start_date>March 2009</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adenosine induced vasodilation</measure>
    <time_frame>following a three day treatment with either heme arginate or L arginine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>heme oxygenase expression and activity</measure>
    <time_frame>assessed during and following a three day treatment with either heme arginate or L-arginine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-arginine treatment first, heme arginate treatment second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heme arginate treatment first, L-arginine treatment second</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine + heme arginate</intervention_name>
    <description>L-arginine first, heme arginate second three day treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heme arginate + L-arginine</intervention_name>
    <description>Heme arginate first, L-arginine second three day treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 and no older than 65 on the day of first dosing

          -  healthy

          -  Quetelet Index (Body Mass Index) of 18 to 30 kg/m2

          -  In general, results of haematology and chemistry should be within the laboratory's
             reference ranges. Determinants of renal and hepatic function should be within twice
             the upper limit of normal range.

        Exclusion Criteria:

          -  Documented history of sensitivity / idiosyncrasy to medicinal products or excipients

          -  history of smoking within the past year

          -  history of or current abuse of drugs, alcohol and/or solvents

          -  Current use of any (over the counter) medication potentially influencing heme
             oxygenase or the cardiovascular system

          -  Inability to understand the nature and extent of the trial and the procedures required

          -  Participation to a drug trial within 60 days prior to the first dose

          -  Febrile illness within 3 days before the first dose

          -  Heterozygosity (LS) or homozygosity (LL) with regard to the number of GT repeats in
             the HO-1 promoter region
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>P. Smits</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

